Massive unmet need for Hypoactive Sexual Desire Disorder treatments addressed by new Female Testosterone product; Phase I and II clinical trials completed. Phase III to be done in ...

Credit: Sprout Pharmaceuticals The approval was based on a randomized, double-blind, placebo-controlled phase 3 trial, which included 447 postmenopausal women with acquired, generalized HSDD.

Cindy Eckert first learned about hypoactive sexual desire disorder (HSDD)—the most common type of sexual dysfunction in women—while attending a conference as a cofounder of Slate Pharmaceuticals, a ...

(StatePoint) Forty-two percent of women experience sexual dysfunction -- and Hypoactive Sexual Desire Disorder (HSDD) -- characterized as frustrating low libido, is the most common form of it. It is ...

Flibanserin, marketed as Addyi, is the first FDA-approved drug for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Clinical trials show it can modestly increase sexual desire ...

The US Food and Drug Administration (FDA) today approved bremelanotide (Vyleesi, AMAG Pharmaceuticals), a first-in-class melanocortin 4 receptor agonist for hypoactive sexual desire disorder (HSDD) in ...

Please provide your email address to receive an email when new articles are posted on . Hypoactive sexual desire disorder is lack of motivation, desire, response or inability to keep interest in sex.